gene therapies

Virginia's budget has expanded Medicaid access to include sickle cell gene therapy. However, providers note that the treatment remains a long, expensive, and difficult process to access.

New rules have been introduced to regulate stem cell and gene therapies under a centralized licensing system, aiming to close a regulatory gap. The amendment focuses on addressing unproven cures but will not immediately lower costs or improve accessibility of these therapies.

David Meek acquired Bluebird Bio (now rebranded as Genetix) when it was near bankruptcy and claims to have transformed it in a year. He predicts the company will treat 1,000 patients annually for sickle cell disease gene therapies by 2030.

Gene therapies can cure diseases like sickle cell with a single treatment but cost over $2 million per patient. The article argues these high costs are justified by long-term savings from avoiding hospitalizations, complications, and lost productivity.

Recent breakthroughs in medicine, including Revolution Medicines' pancreatic cancer treatment and Eli Lilly's anti-obesity drug, show significant progress in extending patient survival and reducing body weight. These advancements stem from decades of research investment but face challenges like high costs and the need for long-term use.

Gene therapies for failing hearts are gaining momentum after years of stagnation. Treatments aim to strengthen failing hearts to restore their function, though the field faces challenges in moving past past controversies.

Adding three common amino acids to lipid nanoparticles can enhance mRNA delivery by 20-fold and CRISPR editing efficiency near 90%, improving treatment outcomes. The method focuses on improving cellular uptake rather than altering the drug itself, offering a potential breakthrough for gene therapies.